Semaglutide vs Tirzepatide

TL;DR

• Semaglutide is a GLP-1 receptor agonist. One target, well-studied, the original of this category.
• Tirzepatide is a dual agonist — it hits both GLP-1 and GIP receptors. Two targets, newer, generally produces larger weight-loss effects in trials.
• The shorthand: semaglutide is single-target, tirzepatide is dual-target.

If you only remember one thing: tirzepatide hits more receptors and tends to produce larger metabolic effects, but it's newer and the long-tail safety data isn't as deep.

The headline difference, in one sentence

Semaglutide pulls one lever (GLP-1). Tirzepatide pulls two (GLP-1 and GIP). More levers usually mean more effect, but also more variables.

What's in each

Both are weekly injections in their primary forms. Both work primarily through appetite reduction, slowed gastric emptying, and improved insulin response. Tirzepatide's additional GIP activity is associated with stronger effects on satiety and glucose handling in research.

Pick semaglutide if...

• You want the most-studied option with the longest real-world track record.
• Cost is a meaningful factor — semaglutide is generally cheaper, more available, and more compoundable.
• You're researching moderate weight-loss or glycemic-control targets, not maximum effect.
• You prefer a single-mechanism approach for cleaner research signal.
• You're considering an oral form — semaglutide has one (Rybelsus); tirzepatide doesn't.

Pick tirzepatide if...

• You're researching maximum weight-loss effect — current head-to-head trials favor tirzepatide.
• You want the dual incretin mechanism that adds GIP activity to GLP-1.
• You're studying type 2 diabetes contexts where the dual mechanism may improve glycemic outcomes.
• The slightly higher cost and somewhat shorter safety record are acceptable tradeoffs for the larger expected effect size.

What GIP actually adds

GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin hormone besides GLP-1. On its own, GIP isn't very useful in obesity research — it doesn't suppress appetite the way GLP-1 does. But when combined with GLP-1 agonism, GIP appears to:

• Enhance insulin secretion in a glucose-dependent way
• Improve adipose tissue handling of glucose and lipids
• Possibly reduce some GI side effects of GLP-1 (still being studied)

The combination produces effects that neither hormone produces alone — which is the whole rationale for tirzepatide's design.

Honest tradeoffs

Both compounds are real, FDA-approved drugs with extensive clinical data — this isn't experimental territory. But the comparison still has nuance:

• Side effects are similar: nausea, GI upset, occasional vomiting in early titration. Tirzepatide may have slightly higher GI side-effect rates at top doses.
• Long-tail data: semaglutide has 7+ years of approved use. Tirzepatide has 4+. If you want maximum certainty about rare adverse events, semaglutide is more proven simply by time.
• Discontinuation effects: both are associated with weight regain after stopping. Neither is a one-and-done treatment.
• Compounding/availability: semaglutide is more widely available in compounded research forms; tirzepatide compounding is more restricted in many jurisdictions.
• Muscle loss concerns: any rapid weight-loss intervention loses some lean mass. Tirzepatide's larger total weight loss means a larger absolute lean mass loss in many subjects unless training and protein intake are managed.

Quick decision shortcut

Where to read more

• Full breakdown of Semaglutide — mechanism, dosing protocols, research context.
• Full breakdown of Tirzepatide — dual-agonist mechanism and trial data.
• The next-generation alternative: Retatrutide, a triple GLP-1/GIP/glucagon agonist still in trials.
• Background on the mechanism: GLP-1 receptor signaling and incretin biology.

Important context

Semaglutide and tirzepatide are FDA-approved prescription medications. They are not over-the-counter supplements. Compounded versions exist in research-supply channels but carry different regulatory status. Nothing on this page is medical advice — these are real drugs with real interactions, contraindications, and monitoring requirements. Discuss with a clinician before any decision about either.